In another single-arm Phase 2 trial, 68 patients diagnosed with advanced pancreatic cancer were vaccinated with a combination of KIF20A peptide and two anti-angiogenic agents targeting VEGFR1 and VEGFR2. Here, KDR is linked to pancreatic neoplasm.